Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03654768
Title Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Southwest Oncology Group
Indications

chronic myeloid leukemia

Therapies

Bosutinib

Dasatinib

Nilotinib

Dasatinib + Ruxolitinib

Bosutinib + Ruxolitinib

Nilotinib + Ruxolitinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.